| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Bacterial cell membrane (antibiotic target); autophagy pathway (autolysosome maturation). DCAP is a broad-spectrum antibiotic that targets the cell membrane of both Gram-positive and Gram-negative bacteria. It also blocks late-stage autophagy by preventing autolysosome maturation and interrupting autophagic flux. DCAP's dual mechanism of action makes it a unique tool for studying both antibacterial and autophagy-related processes.
|
|---|---|
| ln Vitro |
DCAP is a broad-spectrum antibiotic that targets the cell membrane of both Gram-positive and Gram-negative bacteria. It blocks late-stage autophagy by preventing autolysosome maturation and interrupting autophagic flux. Detailed in vitro activity data (MIC values, IC50) are not provided in the available literature.
|
| ln Vivo |
DCAP's in vivo activity has not been extensively reported. As an antibiotic, it may have potential for treating bacterial infections. Its autophagy-inhibiting activity may have implications for cancer research and other diseases where autophagy plays a role. Further studies are needed to characterize its in vivo efficacy.
|
| Enzyme Assay |
In vitro antibacterial susceptibility testing is performed using standard broth microdilution or agar dilution methods. Bacterial strains (Gram-positive and Gram-negative) are cultured in appropriate media and treated with varying concentrations of DCAP. Minimum inhibitory concentrations (MICs) are determined by measuring bacterial growth after overnight incubation.
|
| Cell Assay |
Mammalian cell lines are treated with DCAP at varying concentrations to assess its effects on autophagy. Autophagic flux is measured by Western blotting for LC3-II and p62 levels, or by using fluorescent reporters such as GFP-LC3. Autolysosome maturation is assessed by colocalization of LC3 and lysosomal markers. Cell viability is measured using standard assays.
|
| Animal Protocol |
Animal models of bacterial infection or autophagy-related diseases may be used to study DCAP's in vivo activity. However, detailed in vivo protocols are not available in the literature. Standard animal models of infection (e.g., murine sepsis or pneumonia models) could be used to assess antibacterial efficacy.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of DCAP have not been extensively characterized. It is a small-molecule compound with a molecular formula of C19H22Cl2N2O4. It typically exists as a solid at room temperature. Detailed PK data (Cmax, Tmax, AUC, t1/2) are not available in the literature.
|
| Toxicity/Toxicokinetics |
Toxicological data for DCAP are not available. As a broad-spectrum antibiotic and autophagy inhibitor, its toxicity profile is unknown. Standard laboratory safety practices should be followed when handling the compound. It is not intended for human use.
|
| References | |
| Additional Infomation |
Structure in the first source
DCAP is a research-grade broad-spectrum antibiotic and autophagy inhibitor. CAS: 500015-20-3. Molecular formula: C19H22Cl2N2O4. Synonyms: 2-[3-(3,6-Dichloro-carbazol-9-yl)-2-hydroxy-propylamino]-2-hydroxymethyl-propane-1,3-diol. It targets bacterial cell membranes and blocks late-stage autophagy. For research use only. |
| Molecular Formula |
C19H22N2O4CL2
|
|---|---|
| Molecular Weight |
413.295
|
| Exact Mass |
412.095
|
| CAS # |
500015-20-3
|
| PubChem CID |
16451152
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.3
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
27
|
| Complexity |
448
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OCC(CO)(NCC(O)CN1C2=C(C3=C1C=CC(Cl)=C3)C=C(Cl)C=C2)CO
|
| InChi Key |
GETQKLUOZMYHGE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H22Cl2N2O4/c20-12-1-3-17-15(5-12)16-6-13(21)2-4-18(16)23(17)8-14(27)7-22-19(9-24,10-25)11-26/h1-6,14,22,24-27H,7-11H2
|
| Chemical Name |
2-[[3-(3,6-dichlorocarbazol-9-yl)-2-hydroxypropyl]amino]-2-(hydroxymethyl)propane-1,3-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4195 mL | 12.0977 mL | 24.1955 mL | |
| 5 mM | 0.4839 mL | 2.4195 mL | 4.8391 mL | |
| 10 mM | 0.2420 mL | 1.2098 mL | 2.4195 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
